Discovery and structural characterization of a phospholamban-binding cyclic peptide and design of novel inhibitors of phospholamban

Chemical Biology & Drug Design
Carola TilgmannJouko Levijoki

Abstract

The interplay between cardiac sarcoplasmic Ca(2+)ATPase and phospholamban is a key regulating factor of contraction and relaxation in the cardiac muscle. In heart failure, aberrations in the inhibition of sarcoplasmic Ca(2+)ATPase by phospholamban are associated with anomalies in cardiac functions. In experimental heart failure models, modulation of the interaction between these two proteins has been shown to be a potential therapeutic approach. The aim of our research was to find molecules able to interfere with the inhibitory activity of phospholamban on sarcoplasmic Ca(2+)ATPase. For this purpose, a portion of phospholamban was synthesized and used as target for a phage-display peptide library screening. The cyclic peptide C-Y-W-E-L-E-W-L-P-C-A was found to bind to phospholamban (1-36) with high specificity. Its functional activity was tested in Ca(2+)uptake assays utilizing preparations from cardiac sarcoplasmic reticulum. By synthesizing and testing a series of alanine point-mutated cyclic peptides, we identified which amino acid was important for the inhibition of the phospholamban function. The structures of active and inactive alanine-mutated cyclic peptides, and of phospholamban (1-36), were determined by NMR. This str...Continue Reading

References

Sep 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H TowbinJ Gordon
Mar 1, 1993·Protein Science : a Publication of the Protein Society·T VorherrE Carafoli
Feb 1, 1996·Journal of Molecular Graphics·R KoradiK Wüthrich
Jan 5, 1999·Bioorganic & Medicinal Chemistry Letters·X ZangY H Chu
Oct 26, 1999·Cardiovascular Research·G F Tomaselli, E Marbán
Sep 29, 2000·American Journal of Physiology. Heart and Circulatory Physiology·M YanoM Matsuzaki
May 1, 2001·The Journal of Biological Chemistry·K HaghighiE G Kranias
Jul 11, 2001·Journal of Molecular and Cellular Cardiology·M Periasamy, S Huke
Feb 28, 2002·Circulation·Federica del MonteRoger J Hajjar
May 25, 2002·Molecular and Cellular Biology·Andrew N CarrEvangelia G Kranias
Sep 18, 2002·Journal of Molecular and Cellular Cardiology·Gerd Hasenfuss, Burkert Pieske
Dec 5, 2002·Chembiochem : a European Journal of Chemical Biology·Michael C HutterVolkhard Helms
Dec 14, 2002·Basic Research in Cardiology·Konrad F FrankRobert H G Schwinger
Jan 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Chikashi ToyoshimaDavid H MacLennan
Mar 1, 2003·Science·Joachim P SchmittChristine E Seidman
Mar 18, 2003·The Journal of Clinical Investigation·Kobra HaghighiEvangelia G Kranias
Jan 14, 2004·Biochemistry·Jinhui LiThomas C Squier
May 26, 2005·Biochemical and Biophysical Research Communications·Tomaz BratkovicUros Urleb
Jul 27, 2005·Proceedings of the National Academy of Sciences of the United States of America·Kirill Oxenoid, James J Chou
Oct 8, 2005·The Journal of Biological Chemistry·Gaofeng FanRichard Z Lin
Jul 4, 2006·Journal of Molecular and Cellular Cardiology·Peter VangheluweFrank Wuytack
Mar 28, 2007·Heart Failure Clinics·Jason R Waggoner, Evangelia G Kranias
Jul 27, 2010·Analytical and Bioanalytical Chemistry·Carlo BertucciAngela De Simone

❮ Previous
Next ❯

Citations

Jul 23, 2013·Current Opinion in Structural Biology·Chikashi Toyoshima, Flemming Cornelius

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.